{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:55:31Z","timestamp":1760345731601},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1987,1,1]],"date-time":"1987-01-01T00:00:00Z","timestamp":536457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1987]]},"DOI":"10.1007\/bf00518180","type":"journal-article","created":{"date-parts":[[2004,11,17]],"date-time":"2004-11-17T13:23:50Z","timestamp":1100697830000},"page":"293-296","source":"Crossref","is-referenced-by-count":29,"title":["Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease"],"prefix":"10.1007","volume":"91","author":[{"given":"T.","family":"Sunderland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. N.","family":"Tariot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. A.","family":"Newhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Mellow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. A.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. L.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1192\/bjp.135.3.216","volume":"135","author":"R Adolfsson","year":"1979","unstructured":"Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979) Changes in the brain catecholamines in patients with dementia of the Alzheimer type. Br J Psychiatry 135:216?223","journal-title":"Br J Psychiatry"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/0024-3205(80)90025-9","volume":"27","author":"R Adolfsson","year":"1980","unstructured":"Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B (1980) Increased activity of brain and platelet monoamine oxidase in dementia of the Alzheimer type. Life Sci 27:1029?1034","journal-title":"Life Sci"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/ajp.141.1.97","volume":"141","author":"GS Alexopoulos","year":"1984","unstructured":"Alexopoulos GS, Lieberman KW, Young RC (1984) Platelet MAO activity in primary degenerative dementia. Am J Psychiatry 141:97?99","journal-title":"Am J Psychiatry"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF01252815","volume":"58","author":"K Baraczka","year":"1983","unstructured":"Baraczka K, Fekete MIK, Kanyicska B (1983) Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration. J Neural Transm 58:299?304","journal-title":"J Neural Transm"},{"issue":"2","key":"CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002826-198205020-00004","volume":"5","author":"W Birkmayer","year":"1982","unstructured":"Birkmayer W, Riederer P, Youdim MBH (1982) (-)Deprenyl in the treatment of Parkinson's disease. Clin Neuropharmacol 5(2):195?230","journal-title":"Clin Neuropharmacol"},{"key":"CR6","first-page":"11","volume":"1","author":"DM Bowen","year":"1979","unstructured":"Bowen DM, Spillane JA, Curzon G, Meier-Ruge W, White P, Goodhardt MJ, Iwangoff P, Davison AN (1979) Accelerated aging or selective neuronal loss as an important cause of dementia. Lancet 1:11?14","journal-title":"Lancet"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJM198505303122203","volume":"312","author":"RS Burns","year":"1985","unstructured":"Burns RS, LeWitt P, Ebert MH, Parkenberg H, Kopin IJ (1985) The clinical syndrome of striatal dopamine deficiency: Parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydrop (MPTP). N Engl J Med 312:1418?1421","journal-title":"N Engl J Med"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/0028-3908(84)90100-X","volume":"23","author":"TJ Crow","year":"1984","unstructured":"Crow TJ, Cross AJ, Cooper JJ, Deakin JFW, Ferrier IN, Johnson JA, Joseph MH, Owen F, Poulter M, Lofthouse R, Corsellis JAN, Chambers DR, Blessed G, Perry EK, Perry RH, Tomlinson BE (1984) Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 23:1561?1569","journal-title":"Neuropharmacology"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1212\/WNL.31.1.19","volume":"31","author":"T Eisler","year":"1981","unstructured":"Eisler T, Terawainen H, Nelson R, Krebs H, Weise V, Lake CR, Ebert MH, Whetzel N, Murphy DL, Kopin IJ, Calne DB (1981) Deprenyl in Parkinson disease. Neurology 31:19?23","journal-title":"Neurology"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00433804","volume":"72","author":"N Garrick","year":"1980","unstructured":"Garrick N, Murphy DL (1980) Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 72:27?33","journal-title":"Psychopharmacology"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/265080a0","volume":"265","author":"V Glover","year":"1977","unstructured":"Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine B substrate in man. Nature 265:80?81","journal-title":"Nature"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1192\/bjp.124.3.280","volume":"124","author":"CG Gottfries","year":"1974","unstructured":"Gottfries CG, Kjallquist A, Ponten U, Roos BE, Sundbarg G (1974) Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer's disease. Br J Psychiatry 124:280?287","journal-title":"Br J Psychiatry"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432208","volume":"86","author":"CG Gottfries","year":"1985","unstructured":"Gottfries CG (1985) Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology 86:245?252","journal-title":"Psychopharmacology"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/archneur.1975.00490510088009","volume":"32","author":"VC Hachinski","year":"1975","unstructured":"Hachinski VC, Iliff LD, Phil M, Zilhka E, DuBoular GH, McAllister VA, Marshall J, Russell RWR, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632?637","journal-title":"Arch Neurol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0024-3205(85)90064-5","volume":"46","author":"RE Heikkila","year":"1985","unstructured":"Heikkila RE, Hess A, Davoisin RC (1985) VI. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: Relationships between monoamine oxidase, MPTP metabolism and neurotoxicity. Life Sci 46:231?236","journal-title":"Life Sci"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566?572","journal-title":"Br J Psychiatry"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1126\/science.6849119","volume":"219","author":"IJ Kopin","year":"1983","unstructured":"Kopin IJ, Gordon EK, Jimerson DC, Polinsky RJ (1983) Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 219:73?75","journal-title":"Science"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0165-1781(86)90051-X","volume":"17","author":"M Linnoila","year":"1986","unstructured":"Linnoila M, Guthrie S, Lane EA, Karoum F, Rudorfer M, Potter WZ (1986) Clinical studies on norepinephrine metabolism: How to interpret the numbers. Psychiatry Res 17:229?239","journal-title":"Psychiatry Res"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1471-4159.1979.tb04533.x","volume":"32","author":"LF Major","year":"1979","unstructured":"Major LF, Murphy DL, Lipper S, Gordon E (1979) Effects of clorgyline and pargyline on deaminated metabolites of norepinepherine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem 32:229?231","journal-title":"J Neurochem"},{"key":"CR20","first-page":"977","volume":"26","author":"JJ Mann","year":"1980","unstructured":"Mann JJ, Gershon S (1980) l-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26:977","journal-title":"Life Sci"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1192\/bjp.142.5.508","volume":"142","author":"J Mendelewicz","year":"1983","unstructured":"Mendelewicz J, Youdim MBH (1983) l-Deprenyl, a selective monoamine oxidase type B inhibitor, in the treatment of depression: A double-blind evaluation. Br J Psychiatry 142:508?511","journal-title":"Br J Psychiatry"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00431109","volume":"73","author":"N Mendis","year":"1981","unstructured":"Mendis N, Pare CMB, Sandler M, Glover V, Stern GM (1981) Is the failure of (-) deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect. Psychopharmacology 73:87?90","journal-title":"Psychopharmacology"},{"key":"CR23","first-page":"49","volume":"169","author":"JD Parkes","year":"1974","unstructured":"Parkes JD, Marsden CD, Rees JE, Curzon G, Kantamaneni BD, Knill-Jones R, Akbar A, Das S, Kataria M (1974) Parkinson's disease, cerebral arteriosclerosis and senile dementia. Q J Med 169:49?61","journal-title":"Q J Med"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archpsyc.1984.01790150033006","volume":"41","author":"MA Raskind","year":"1984","unstructured":"Raskind MA, Peskind ER, Halter JB, Jimerson DC (1984) Norepinepherine and MHPG levels in CSF and plasma of Alzheimer's disease. Arch Gen Psychiatry 41:343?346","journal-title":"Arch Gen Psychiatry"},{"key":"CR25","volume-title":"Monoamine oxidase and disease: prospects for therapy with reversible inhibitors","author":"P Riederer","year":"1984","unstructured":"Riederer P, Fellinger K, Seeman D (1984) Monoamine oxidase and Parkinsonism. In: Tipton KF, Dostert P, Benedetti MS (eds) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic Press London"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/archpsyc.1971.01750120052009","volume":"24","author":"DS Robinson","year":"1971","unstructured":"Robinson DS, Davis JM, Nies A, Ravaris CL, Sylwester D (1971) Relation of sex and aging to monoamine oxidase activity in human brain, plasma and platelets. Arch Gen Psychiatry 24:536?539","journal-title":"Arch Gen Psychiatry"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0003-2697(83)90162-8","volume":"131","author":"M Scheinin","year":"1983","unstructured":"Scheinin M, Chank W, Kirk KL, Linnoila M (1983) Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection. Anal Biochem 131:246?253","journal-title":"Anal Biochem"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0404.1981.tb04392.x","volume":"64","author":"H Soininen","year":"1981","unstructured":"Soininen H, MacDonald E, Rekonen M, Riekkinen PJ (1981) Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of the Alzheimer type. Acta Neurol Scand 64:101?107","journal-title":"Acta Neurol Scand"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF01246961","volume":"43","author":"GM Stern","year":"1978","unstructured":"Stern GM, Lees AJ, Sandler M (1978) Recent observations on the clinical phrmacology of (-)deprenyl. J Neural Transm 43:245?251","journal-title":"J Neural Transm"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF00427904","volume":"36","author":"T Sunderland","year":"1985","unstructured":"Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 36:432?437","journal-title":"Psychopharmacology"},{"key":"CR31","first-page":"289","volume":"23","author":"E Varga","year":"1967","unstructured":"Varga E, Tringer L (1967) Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCL, E-250). Acta Med Acad Sci Hung Tomus 23:289?295","journal-title":"Acta Med Acad Sci Hung Tomus"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/archneur.1985.04060020037011","volume":"42","author":"L Volicer","year":"1985","unstructured":"Volicer L, Direnfield LK, Freedman M, Albert ML, Langlais PJ, Bird EA (1985) Serotonin and 5-hydroxyindoleacetic acid in CSF: difference in Parkinson's disease and dementia of the Alzheimer's type. Arch Neurol 42:127?129","journal-title":"Arch Neurol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.3875898","volume":"230","author":"KN Westlund","year":"1985","unstructured":"Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230:181?183","journal-title":"Science"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/0024-3205(82)90099-6","volume":"31","author":"PL Wood","year":"1982","unstructured":"Wood PL, Etienne P, Lal S, Gauthier S, Cajal S, Nair NPV (1982) Reduced lumbar CSF somatostatin levels in Alzheimer's disease. Life Sci 31:2073?2079","journal-title":"Life Sci"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00518180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00518180\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00518180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T18:57:20Z","timestamp":1554404240000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00518180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1987]]}},"alternative-id":["BF00518180"],"URL":"https:\/\/doi.org\/10.1007\/bf00518180","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987]]}}}